Stock TRI TRIVARX LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials TrivarX Limited

Equities

TRI

AU0000300196

Pharmaceuticals

End-of-day quote Australian S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
0.026 AUD 0.00% Intraday chart for TrivarX Limited +8.33% -13.33%
Feb. 28 TrivarX Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Feb. 09 TrivarX Signs Collaboration with Northern Michigan University on Sleep Research MT

Valuation

Fiscal Period: Juni 2018 2019 2020 2021 2022 2023
Capitalization 1 27.35 2.239 6.569 12.57 4.135 4.548
Enterprise Value (EV) 1 21.35 3.659 5.833 10.28 3.169 4.444
P/E ratio -1.53 x -0.3 x -1.36 x -6.93 x -0.24 x -1.11 x
Yield - - - - - -
Capitalization / Revenue 11.1 x 0.55 x 7.1 x 9.94 x 4.11 x 4.74 x
EV / Revenue 8.67 x 0.89 x 6.3 x 8.13 x 3.15 x 4.63 x
EV / EBITDA -1.41 x -0.77 x -1.67 x -8.07 x -1.42 x -3.71 x
EV / FCF -3.74 x -0.61 x -1.66 x -4.17 x -0.85 x -1.85 x
FCF Yield -26.8% -163% -60.3% -24% -118% -54.1%
Price to Book 1.96 x 0.26 x 0.52 x 0.77 x 0.58 x 0.72 x
Nbr of stocks (in thousands) 10,131 12,440 54,740 89,753 137,825 227,396
Reference price 2 2.700 0.1800 0.1200 0.1400 0.0300 0.0200
Announcement Date 9/14/18 9/27/19 9/25/20 8/31/21 9/30/22 9/28/23
1AUD in Million2AUD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Juni 2018 2019 2020 2021 2022 2023
Net sales 1 2.462 4.102 0.9253 1.264 1.005 0.9605
EBITDA 1 -15.12 -4.754 -3.491 -1.273 -2.224 -1.198
EBIT 1 -16.43 -6.062 -3.64 -1.472 -2.673 -1.739
Operating Margin -667.35% -147.76% -393.37% -116.38% -265.83% -181.08%
Earnings before Tax (EBT) 1 -16.3 -6.587 -3.872 -1.487 -12.72 -3.071
Net income 1 -16.3 -6.587 -3.872 -1.487 -12.72 -3.071
Net margin -662.05% -160.57% -418.52% -117.57% -1,264.69% -319.7%
EPS 2 -1.761 -0.6091 -0.0880 -0.0202 -0.1240 -0.0180
Free Cash Flow 1 -5.716 -5.971 -3.517 -2.467 -3.73 -2.403
FCF margin -232.15% -145.55% -380.15% -195.1% -370.95% -250.15%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 9/14/18 9/27/19 9/25/20 8/31/21 9/30/22 9/28/23
1AUD in Million2AUD
Estimates

Balance Sheet Analysis

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net Debt 1 - 1.42 - - - -
Net Cash position 1 6 - 0.74 2.29 0.97 0.1
Leverage (Debt/EBITDA) - -0.2988 x - - - -
Free Cash Flow 1 -5.72 -5.97 -3.52 -2.47 -3.73 -2.4
ROE (net income / shareholders' equity) -119% -58.3% -36.5% -10.2% -108% -45.7%
ROA (Net income/ Total Assets) -53.6% -23.4% -16.7% -5.86% -12.9% -13.2%
Assets 1 30.41 28.14 23.25 25.37 98.45 23.33
Book Value Per Share 2 1.380 0.6900 0.2300 0.1800 0.0500 0.0300
Cash Flow per Share 2 0.6000 0.1100 0.0100 0.0300 0.0100 0
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 9/14/18 9/27/19 9/25/20 8/31/21 9/30/22 9/28/23
1AUD in Million2AUD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

1st Jan change Capi.
TRIVARX LIMITED Stock TrivarX Limited
-13.33% 5.74M
MERCK KGAA Stock Merck KGaA
+5.31% 70.44B
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+10.97% 8.94B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-16.83% 4.75B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+43.48% 4.5B
YUHAN CORPORATION Stock Yuhan Corporation
+3.20% 3.85B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-21.36% 2.34B
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-29.67% 2.2B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+8.38% 1.96B
SUPERNUS PHARMACEUTICALS, INC. Stock Supernus Pharmaceuticals, Inc.
+3.90% 1.65B
Specialty & Advanced Pharmaceuticals
  1. Stock Market
  2. Equities
  3. TRI Stock
  4. Financials TrivarX Limited